SIRPant technology employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells. The approach results in a polyclonal immune response against multiple tumor antigens. The therapy has broad applicability for unmet needs in the treatment of solid tumors.
Active Portfolio Company
https://sirpantimmunotx.com/
Location: United States, Pennsylvania, Chambersburg
Investors 4
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
| - | Georgia Re... | gra.org |
| - | GRA Ventur... | graventure... |
| - | SeedFolio | seedfolio.... |